Cargando…

CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study

Serum cytokeratin 19 fragment (CYFRA21-1) has been found to be a useful prognostic marker in lung cancer. Previous studies have revealed that change in CYFRA21-1 synchronously predicted therapeutic effectiveness in advanced nonsmall cell lung cancer (NSCLC) after the second cycle of chemotherapy. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Tongwei, Jin, Ying, Mao, Guangyun, Wei, Yaping, Wu, Guoqing, Ye, Xiao, Zhou, Yonglie, Yuan, Guorong, Gao, Liang, Hong, Yupeng, Chen, Yun, Hong, Chaojin, Zhou, Hongying, Su, Dan, Qin, Zhiquan, Lu, Liqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207583/ https://www.ncbi.nlm.nih.gov/pubmed/28033287 http://dx.doi.org/10.1097/MD.0000000000005748

Ejemplares similares

The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer
por: Zhao, Tongwei, et al.
Publicado: (2021)

CYFRA21-1/TG ratio as an accurate risk factor to predict eye metastasis in nasopharyngeal carcinoma: A STROBE-compliant article
por: Peng, Sheng-Jia, et al.
Publicado: (2020)

Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer
por: Shang, Liqun, et al.
Publicado: (2021)

Retracted: Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Mao, Chen, et al.
Publicado: (2015)

The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Clinical and prognostic significance of Merkel cell polyomavirus in nonsmall cell lung cancer
por: Kim, Gun-Jik, et al.
Publicado: (2017)

A comprehensive bioinformatics analysis of FOXP3 in nonsmall cell lung cancer
por: Zhu, Jianfei, et al.
Publicado: (2022)

Preliminary study on the clinical significance of kinesin Kif18a in nonsmall cell lung cancer: An analysis of 100 cases
por: Guo, Weifeng, et al.
Publicado: (2020)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
por: Gu, Biao, et al.
Publicado: (2016)

Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer
por: Zhang, Xiaojun, et al.
Publicado: (2017)

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
por: Ding, Lin, et al.
Publicado: (2016)

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
por: Cui, Guanghui, et al.
Publicado: (2017)

Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer: A 10-year cohort study
por: Shen-Tu, Yang, et al.
Publicado: (2017)

Effect of mu Agonists on Long-Term Survival and Recurrence in Nonsmall Cell Lung Cancer Patients
por: Wang, Kai, et al.
Publicado: (2015)

The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis
por: Luo, Hui, et al.
Publicado: (2017)

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution
por: He, Xiaobo, et al.
Publicado: (2016)

(125)I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy
por: Xiang, Zhanwang, et al.
Publicado: (2015)

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
por: Ma, Hu, et al.
Publicado: (2016)

The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review
por: Chen, Yu Jie, et al.
Publicado: (2015)

Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
por: Zhou, Guo-Wu, et al.
Publicado: (2016)

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
por: Yuan, Jin-Qiu, et al.
Publicado: (2017)

Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy?
por: Nguyen, Nam P., et al.
Publicado: (2016)

Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18: A case report
por: Wu, Yimin, et al.
Publicado: (2017)

Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer
por: Liang, Wenjun, et al.
Publicado: (2016)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer – A retrospective analysis
por: Kong, Pengyu, et al.
Publicado: (2017)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases
por: Zhong, Jinman, et al.
Publicado: (2016)

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis
por: Liu, Yafang, et al.
Publicado: (2016)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

CXCL14 and NOS1 expression in specimens from patients with stage I–IIIA nonsmall cell lung cancer after curative resection
por: Ji, Xiaoqin, et al.
Publicado: (2018)

Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy
por: Koh, Young W., et al.
Publicado: (2017)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2rdfagkqg74gpfmufvpl6bgpog